HEMO
NEUTRALHemogenyx Pharmaceuticals Provides Update on Share Admission
The biopharmaceutical group provides an update on the admission of new ordinary shares, with the FCA scheduling the admission hearing for early January 2026.
Hemogenyx Pharmaceuticals
600.00GBX
-5.36%
Market Cap
36.25M
Volume
16.67k
33% of avg
P/E Ratio
NaN
EPS (TTM)
Beta
1.39
Day Range
572.29p - 630.00p
52 Week Range
124.00p600.00p1,800.00p
600.00p
Upcoming Events
HEMO
BADHemogenyx Pharmaceuticals Raises £190,000 Through Warrant Exercises
The biotechnology company has raised £190,000 through the exercise of warrants, but the new shares were issued at a 72.9% discount to the previous closing price, a concerning sign for investors.
HEMO
NEUTRALHemogenyx Pharmaceuticals Announces Director Dealings
The biotechnology company has announced changes to its major shareholders.
HEMO
NEUTRALHemogenyx Pharmaceuticals Provides Clinical Trial Update
The biotechnology company provides an update on its ongoing Phase I clinical trial for its HG-CT-1 therapy, including DSMB clearance to advance to the next dose level and the initiation of pediatric patient recruitment.
HEMO
NEUTRALHemogenyx Pharmaceuticals Receives Clearance for Pediatric Enrolment in HG-CT-1 Trial
The biotechnology company has received clearance to enroll children and adolescents in its ongoing HG-CT-1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia.
HEMO
BADHemogenyx Pharmaceuticals Reports Clinical Progress Amid Financial Challenges
The biopharmaceutical firm reports promising clinical progress in its Phase I trial for AML treatment. However, financial challenges loom with doubled losses and urgent funding needs.
HEMO
GOODHemogenyx Pharmaceuticals Signs Letter of Intent to Advance HG-CT-1 CAR-T Therapy in Estonia
The biotechnology company has signed a letter of intent with a leading Estonian cell therapy firm to advance the commercialization of its HG-CT-1 CAR-T therapy for relapsed or refractory acute myeloid leukemia.
HEMO
NEUTRALHemogenyx Pharmaceuticals Announces Holding(s) in Company
The healthcare company has announced changes to its major shareholders.
HEMO
NEUTRALHemogenyx Pharmaceuticals Provides Update on HG-CT-1 CAR-T Therapy Trial
The biotechnology company reports successful treatment of a third patient in the ongoing clinical trial of its HG-CT-1 CAR-T therapy for relapsed/refractory acute myeloid leukemia.
HEMO
NEUTRALHemogenyx Pharmaceuticals Invited to Prestigious DCNY Summit
The biotechnology company has been invited to present at the upcoming DCNY Summit, a prestigious event connecting policymakers, investors, and innovators.